Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, today announced that the U.S. Patent and Trademark Office (USPTO) has granted patent of the pharmaceutical compositions of its investigational SARS-CoV-2 Specific Allogeneic T cell therapy for treatment of COVID-19 (US 11,207,401). The patent reinforces Tevogen’s growing IP portfolio which already includes a patent that covers method of treatment of COVID-19 using SARS-COV-2 Specific Allogeneic Cytotoxic T Lymphocytes.
Dr. Neal Flomenberg, M.D., Chairman of Tevogen’s Scientific Advisory Board stated, “The magnitude of mutations in Omicron and the variant’s impact on almost all available monoclonal antibodies and vaccines, are concerning. I am hopeful about Protease Inhibitors, another tool against this virus. However, the narrow window of time between confirmed diagnosis and administration to get therapeutic benefit, and interactions with commonly used drugs in many high-risk patients, is a challenge. One advantage of TVGN-489 recognizing multiple targets spread across the entire viral genome is that this helps mitigate the impact of mutations.”
Tevogen CEO Dr. Ryan Saadi, M.D., M.P.H. added, “While publication of this patent is another major milestone for Tevogen and I am hopeful that TVGN-489 will play a critical role in overcoming the biggest public health crisis of our time, we must prioritize basic public health measures to reduce infections. COVID-19 related health complications can be debilitating for our society and our economy. A collaborative approach encompassing all stakeholders is essential to overcome this prolonged pandemic.”
TVGN-489 is currently in clinical trial for high-risk patients (TCTL) at Thomas Jefferson University in Philadelphia. Trial details and recruitment information are available at Clinical Trials - Tevogen.
TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte product, which detects targets spread across the entire viral genome. These targeted CTLs are expected to recognize and kill off virally infected cells, allowing the body to replace them with healthy, uninfected cells. TVGN-489 has already demonstrated strong antiviral activity against SARS-CoV-2 in preclinical studies.
About Tevogen Bio
Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.
This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc.’s (the “Company”) development and patient access of its innovations in infectious diseases and oncology. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the company’s control which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, sales, pricing and actions by the FDA/EMA. The Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and make no representations or warranties in connection herewith or with respect to any omissions herefrom.
Corporate Communications Lead